CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
-
Published:2022-12-15
Issue:5
Volume:10
Page:460-471
-
ISSN:2413-2241
-
Container-title:Pharmacy & Pharmacology
-
language:
-
Short-container-title:Farm. farmakol. (Pâtigorsk)
Author:
Tavlueva E. V.1ORCID, Zernova E. V.1ORCID, Kutepova M. P.1ORCID, Kostina N. E.2ORCID, Lesina V. S.2ORCID, Mould D. R.3ORCID, Ito K.3, Zinchenko A. V.4ORCID, Dolgorukova A. N.4ORCID, Nikolskaya M. V.4ORCID, Lemak M. S.4ORCID, Filon O. V.4ORCID, Samsonov M. Yu.4ORCID
Affiliation:
1. Inozemtsev Municipal Clinical Hospital 2. Voronezh Regional Clinical Hospital No. 1 3. Projections Research, Inc 4. Joint Stock Company “R-Pharm”
Abstract
The aim of the article is to study pharmacokinetic characteristics of intravenous olokizumab in patients with moderate COVID-19 to relieve a hyperinflammation syndrome.Materials and methods. The pharmacokinetic study was conducted as a part of a phase III clinical study (RESET, NCT05187793) on the efficacy and safety of a new olokizumab regimen (intravenous, at the doses of 128 mg or 256 mg) in COVID-19 patients. Plasma concentrations of olokizumab were determined by the enzyme immunoassay. The population analysis was performed using a previously developed pharmacokinetic model based on a linear two compartment.Results. The pharmacokinetic analysis included the data from 8 moderate COVID-19 patients who had been administrated with olokizumab intravenously at the dose of 128 mg. According to the analysis results in this population, there was an increase in the drug clearance, compared with the data obtained in healthy volunteers and the patients with rheumatoid arthritis: 0.435, 0.178 and 0.147 l/day, respectively. The parameters analysis within the framework of a population pharmacokinetic model showed that the main factors for the increased olokizumab clearance are a high body mass index. In addition, the presence of COVID-19 itself is an independent factor in increasing the drug clearance.Conclusion. After the intravenous olokizumab administration, an increase in the drug clearance is observed in moderate COVID-19 patients against the background of the disease course. The main contribution to the increased clearance is made by the characteristics of the population of COVID-19 patients associated with the risk of a severe disease and inflammation. When administered intravenously at the dose of 128 mg, a therapeutically significant olokizumab level was maintained throughout the acute disease phase for 28 days.
Publisher
Volgograd State Medical University
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Pharmacy,Pharmacology (nursing)
Reference26 articles.
1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. DOI: 10.1038/s41586-020-2012-7 2. Zhou J, He W, Liang J, Wang L, Yu X, Bao M, Liu H. Association of Interleukin-6 Levels with Morbidity and Mortality in Patients with Coronavirus Disease 2019 (COVID-19). Jpn J Infect Dis. 2021 Jul 21;74(4):293–8. DOI: 10.7883/yoken.JJID.2020.463 3. Luo K, Chen Y, Yang J, Tao Q, Luo M. Liver Injury and Elevated Levels of Interleukins, Interleukin-2 Receptor, and Interleukin-6 Predict the Severity in Patients With COVID-19. Front Public Health. 2021 Dec 14;9:778340. DOI: 10.3389/fpubh.2021.778340 4. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, Kronbichler A, Shin JI. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021 Jan 1;11(1):316–29. DOI: 10.7150/thno.49713 5. Yu SY, Koh DH, Choi M, Ryoo S, Huh K, Yeom JS, Yoon YK. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerg Microbes Infect. 2022 Dec;11(1):1154–65. DOI: 10.1080/22221751.2022.2059405
|
|